✓ Translated by DotMD AI Clinical Council Source: Bone marrow transplantation • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #38664589 ↗

Phase III Randomized Trial: Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC) (N = 64)

Original Paper Title: “Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC)”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
N = 64
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • In a multivariate analysis, ECOG status and chemotherapy prior to HCT were independent risk factors for OS and RFS, ECOG and low cytogenetic risk for NRM and chemotherapy prior to HCT for RI. Patients with low cytogenetic risk had better OS [p = 0.002], RFS [p = 0.02], and NRM (p = 0.015) after RIC as compared to MAC.
  • Study Design & Sample: Phase III Randomized Trial published in Bone marrow transplantation (N = 64 human participants).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Bone marrow transplantation (2024), this phase iii randomized trial evaluating 64 human participants investigated: Short-term outcome of myeloablative (MAC) and reduced intensity (RIC) conditioning in the prospective randomized international EBMT RICMAC study in patients with myelodyplastic syndrome (MDS) was comparable but longer follow up is lacking. Key clinical takeaway: In a multivariate analysis, ECOG status and chemotherapy prior to HCT were independent risk factors for OS and RFS, ECOG and low cytogenetic risk for NRM and chemotherapy prior to HCT for RI. Patients with low cytogenetic risk had better OS [p = 0.002], RFS [p = 0.02], and NRM (p =...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Bone marrow transplantation, 2024-08-15; N = 64; Rigor 82/100): In a multivariate analysis, ECOG status and chemotherapy prior to HCT were independent risk factors for OS and RFS, ECOG and low cytogenetic risk for NRM and chemotherapy prior to HCT for RI. Patients with low cytogenetic risk had better OS [p = 0.002], RFS [p = 0.02], and NRM (p = 0.015) after RIC as compared to MAC.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: glutathione-injection → Rx: busulfan → Rx: cyclophosphamide → Rx: fludarabine-phosphate → Condition: myelodysplastic-syndromes → Condition: cut-laceration → Condition: confusion →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 38664589: Phase III Randomized Trial: Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC) (N = 64)

3 of 3 Free Questions Remaining